Acuitas Therapeutics

Headquarters

6190 Agronomy Road, Suite 402 Vancouver BC V6T 1Z3 Canada

Email: info@acuitastx.com
Facebook: @Acuitas
Twitter: @Acuitastx
Acuitas: noun, insight, perception, sharpness.

PUBLICATIONS

Acuitas Scientists, in Collaboration With Other Researchers, Have Published Extensively on LNP Development and Characterization.

KEY PUBLICATIONS

Huysmans et al. (2019) “Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin” Mol Ther.Nucleic Acids DOI: 10.1016/j.omtn.2019.08.001

Pardi et al. (2019) “Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques” Mol Ther.Nucleic Acids DOI: 10.1016/j.omtn.2019.03.003

Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Mol Ther DOI: 10.1016/j.ymthe.2019.03.003

Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” J Control Release DOI:10.1016/j.jconrel.2018.10.015

Pardi et al. (2018b) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies”  Nature Communications DOI:10.1038/s41467-018-05482-0

Pardi et al. (2018a) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine DOI:10.1084/jem.20171450

Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines DOI:10.1038/s41541-017-0032-6

Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine DOI:10.15252/emmm.201707678

Pardi et al. (2017b) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge Nature Communications DOI:10.1038/ncomms14630

Pardi et al. (2017a) Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature DOI:10.1038/nature21428

Pardi et al. (2015) Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes J Controlled Release DOI:10.1016/j.jconrel.2015.08.007

Thess et al. (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals Mol Ther DOI:10.1038/mt.2015.103

Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Mol Ther Nucleic Acids DOI:10.1038/mtna.2013.66

Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Mol Ther DOI:10.1038/mt.2013.124

Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angew Chem Int Ed Engl DOI:10.1002/anie.201203263

Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nat Biotechnol DOI:10.1038/nbt.1602

Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Mol Ther DOI:10.1038/mt.2010.85